Quassinoids from Ailanthus excelsa

Three quassinoids, 1, 2 and 3, 4-dihydro excelsin 3 were isolated from the stem bark of Ailanthus excelsa, along with five known quassinoids excelsin, glaucarubine, ailanthinone, glaucarubinone and glaucarubolone. The glaucarubolone has been isolated for the first time from this plant. The structural elucidation is based on the analysis of spectroscopic data.     

Structural requirements of quassinoids for the inhibition of cell transformation

The effects of eleven quassinoids on Rous sarcoma virus induced cell transformation and on growth of normal cells were examined. At concentrations of 0.15-1 μg/ml they inhibited foci formation (76–99 %) without toxic effects on normal cells. The most active compounds also affected virus production by transformed cells. In intact normal and transformed cells, protein and DNA synthesis was equally affected after 3 hours of exposure to quassinoids of both cell types. RNA synthesis was not inhibited. This study has shown that the structural requirement of a C-15 ester in the quassinoids for antileukemic activity $\text{in vitro}$ and $\text{in vivo}$ is not essential for their antitransforming activity.     

Quassinoid glucosides from seeds of Brucea amarissima

Quassinoid glucosides, javanicosides I, J, K and L, were isolated from the seeds of Brucea amarissima (Lour.) Desv. ex B. A. Gomes (Simaroubaceae), along with two known quassinoids, i.e. bruceins D and E, and seven known quassinoid glucosides, yadanziosides B, C, E, I and K, bruceoside B and yadanzigan. Their structures were elucidated by analysis of the spectral data and chemical evidence.     

Quassinoids from the leaves of the Madagascan Simaroubaceae Samadera madagascariensis

An investigation of the leaves of the Madagascan Simaroubaceae Samadera madagascariensis has yielded three C18 quassinoids, 5beta,6-dihydrosamaderine A, 2-chlorosamaderine A, and samaderolactone A, and a C19 quassinoid, 3,4beta-dihydrosamaderine C, together with the known quassinoids samaderine A, samaderine B, and cedronin. The compounds isolated displayed little or no anti-tumour activity.     

Antifeedant and Insecticidal Activity of Quassinoids against Diamondback Moth (Plutella xylostella)

The antifeedant and insecticidal activities of sixteen quassinoids against 3rd instar larvae of the diamondback moth (Plutella xylostella) were compared with those of known insect antifeedant chlordimeform (1), and the structure-activity relationship was discussed. The insecticidal activity of quassin (2) was higher than that of 1, although its antifeedant activity was nearly the same as that of the reference compound.     

Incorporation of Serine-3-14C into Sphingolipid by Rat Liver Particulate

Four semi-synthetic and fourteen quassinoids were tested for their antifeedant and insecticidal activity against 3rd instar larvae of the diamondback moth (Plutella xylostella). In this quassinoid series, isobrucein-B was the most potent compound in both assays. Chemical conversion of the methoxy and/or methylenedioxy groups in the A and C rings to hydroxy groups among these quassinoids resulted in decreased activity.     

Cytotoxic quassinoids from Ailanthus altissima

Two new quassinoids, altissinol A (1) and B (7), together with 12 known quassinoids, were isolated from the 95% ethanol extract of the barks of Ailanthus altissima. The structures of the new compounds (1 and 7) were determined on the basis of the spectroscopic methods including UV, IR, HR-ESI-MS, 1D and 2D NMR. The cytotoxic potential of all isolates were evaluated in vitro against three human hepatoma cell lines. Quassinoids 1–7 displayed potent cytotoxic activities against human hepatoma Hep3B and HepG2 cell lines. Interestingly, compounds 2, 3, and 5 exhibited cytotoxic activity against multidrug resistance HepG2/ADM cell line with IC₅₀ value 4.3-fold more sensitive to Doxorubicin (DOX).     

Quassinoids from the twigs and thorns of Castela polyandra

The structures of six new C20 quassinoids and one new C19 quassinoid, all isolated from the twigs and thorns of Castela polyandra, were established by a combination of spectroscopic and single-crystal X-ray analysis. Five known quassinoids and one known sterol were also identified.     

LC-MS/MS-based metabolites of Eurycoma longifolia (Tongkat Ali) in Malaysia (Perak and Pahang)

A number of three LC-MS/MS hybrid systems (QTof, TripleTof and QTrap) has been used to profile small metabolites (m/z 100-1000) and to detect the targeted metabolites such as quassinoids, alkaloids, triterpene and biphenylneolignans from the aqueous extracts of Eurycoma longifolia. The metabolite profiles of small molecules showed four significant clusters in the principle component analysis for the aqueous extracts of E. longifolia, which had been collected from different geographical terrains (Perak and Pahang) and processed at different extraction temperatures (35°C and 100°C). A small peptide of leucine (m/z 679) and a new hydroxyl methyl β-carboline propionic acid have been identified to differentiate E. longifolia extracts that prepared at 35°C and 100°C, respectively. From the targeted metabolites identification, it was found that 3,4?-dihydroeurycomanone (quassinoids) and eurylene (squalene-type triterpene) could only be detected in the Pahang extract, whereas canthin-6-one-3N-oxide could only be detected in the Perak extract. Overall, quassinoids were present in the highest concentration, particularly eurycomanone and its derivatives compared to the other groups of metabolites. However, the concentration of canthin-6-one and β-carboline alkaloids was significantly increased when the roots of the plant samples were extracted at 100°C.     

Five new quassinoids and cytotoxic constituents from the roots of Eurycoma longifolia

Eurycoma longifolia has been widely used for various traditional medicinal purposes in South-East Asia. In this study, five new quassinoids, eurylactone E (1), eurylactone F (2), eurylactone G (3), eurycomalide D (4), and eurycomalide E (5), along with ten known quassinoids (6–15) were isolated from the roots of E. longifolia. Their structures were determined by extensive spectroscopic methods, including 1D and 2D NMR, and MS spectra data. Among the isolated compounds, 13β-methyl,21-dihydroeurycomanone (6) has been reported as a synthetic derivative. However, it was isolated from the natural product for the first time in this study. The cytotoxic activities of fifteen compounds were evaluated against human lung cancer cell line, A549 and human cervical cancer cell line, HeLa.     

Canthin-6-one,undulatone and two quassinoids from Hannoa klaineana roots

Canthin-6-one, scopoletin, undulatone and two new quassinoids, 15-desacetylundulatone and 6α-tigloyloxyglaucarubol were isolated from Hannoa klaineana roots; quassinoids were obtained in high yields from this plant material.     

Quassinoids from Eurycoma harmandiana.

Three quassinoids, iandonosides A and B and iandonone, were isolated from the root of Eurycoma harmandiana, along with five known quassinoids, casteloside B, 13 beta, 21-dihydroeurycomanone, chaparrinone, glaucarubolone and ailanquassin B as well as the coumarin, scopoletin. The structural elucidations were based on analyses of spectroscopic data.     

Javanicinosides D-H, quassinoid glucosides from Picrasma javanica

From Picrasma javanica, five new quassinoid glucosides, javanicinosides D-H, together with known quassinoids, neoquassin and picrasin A and triterpenoids, hispidol A and lanosta-7,24-dien-3-one were isolated. The structures have been determined by spectral analysis and chemical evidence.     

鸦胆子抗肿瘤活性成分的化学研究

从苦木科植物鸦胆子[Brucea javanica(L.)Merr]干躁果实的硅胶干柱柱层析所得的活性部位中经层析分离得到7个四环三萜苦木内酯成份(A,B,C,D,E,F,G),经UV,IR,~1H-NMR,~(13)C-NMR等方法鉴定分别为鸦胆苦醇(Brusatol A),双氢鸦胆苦醇(Dihydrobrusatol,B),鸦胆因B(Bruceine B,C),鸦胆因D(Bruceine D,D),鸦胆因H(Bruceine H,E),鸦胆子甙A(Bruceoside A,F)和双氢鸦胆子甙A(Yadanzioside A,G)。据报道,鸦胆苦醇和鸦胆子甙A具有较强的抗肿瘤活性。     

Quassinoids from Eurycoma longifolia as plant growth inhibitors.

Seven quassinoids including a new 12-epi-11-dehydroklaineanone were isolated from the leaves of Eurycoma longifolia (Simaroubaceae) as plant growth inhibitors or related compounds. The strongest activity was found in 14,15beta-dihydroxyklaineanone.     

Chemical Constituents of the Branches and Leaves of Picrasma chinensis P.Y. Chen and Tyrosinase Inhibiting Activity

One new alkaloid, picrasine A, two new quassinoids, picralactones A−B, together with eleven known compounds were isolated from Picrasma chinensis P.Y. Chen. The structures of these compounds were determined using 1D and 2D NMR, HR-ESI-MS, and IR spectroscopic data, and by comparison with published data. Some compounds were tested for tyrosinase inhibiting activity, however, none of them exhibited strong inhibitory effects.     

Quassinoids Exhibit Greater Selectivity Against Plasmodium Falciparum Than Against Entamoeba Histolytica, Giardia Intestinalis Or Toxoplasma Gondii In Vitro

ABSTRACT. The in vitro activities of a series of quassinoids against Plasmodium falciparum, Entamoeba histolytica, Giardia intestinalis and Toxoplasma gondii have been compared with their in vitro cytotoxic effects against KB cells (human epidermoid carcinoma of the nasopharynx). All of the compounds tested were more toxic to KB cells than to G. intestinalis , but four (ailanthinone, bruceine D, brusatol and glaucarubinone) were slightly less toxic to KB cells than to E. histolytica. Glaucarubinone was similarly more toxic to intracellular T. gondii than to KB cells but ailanthinone was more selective (36 times more toxic to T. gondii than to KB cells). All of the compounds were more toxic to P. falciparum than to KB cells; the most selective quassinoids—glaucarubinone, bruceine D, ailanthinone and brusatoi—were found to have toxicity/activity ratios of 285, 76, 48 and 32 respectively. These results suggest that quassinoids have a selective action on P. falciparum. Further studies to elucidate the basis for this are in progress.     

The In Vitro and In Vivo Anti-Cancer Activities of a Standardized Quassinoids Composition from Eurycoma longifolia on LNCaP Human Prostate Cancer Cells

Quassinoids are a group of diterpenoids found in plants from the Simaroubaceae family. They are also the major bioactive compounds found in Eurycoma longifolia which is commonly used as traditional medicine in South East Asia to treat various ailments including sexual dysfunction and infertility. These uses are attributed to its ability to improve testosterone level in men. Chronic consumption of E. longifolia extracts has been reported to increase testosterone level in men and animal model but its effect on prostate growth remains unknown. Therefore, the present study investigates the effects of a standardized total quassinoids composition (SQ40) containing 40% of the total quassinoids found in E. longifolia on LNCaP human prostate cancer cell line. SQ40 inhibited LNCaP cell growth at IC₅₀ value of 5.97 μg/mL while the IC₅₀ on RWPE-1 human prostate normal cells was 59.26 μg/mL. SQ40 also inhibited 5α-dihydrotestosterone-stimulated growth in LNCaP cells dose-dependently. The inhibitory effect of SQ40 in anchorage-independent growth of LNCaP cells was also demonstrated using soft agar assay. SQ40 suppressed LNCaP cell growth via G₀/G₁ phase arrest which was accompanied by the down-regulation of CDK4, CDK2, Cyclin D1 and Cyclin D3 and up-regulation of p21^Waf1/Cip1 protein levels. SQ40 at higher concentrations or longer treatment duration can cause G₂M growth arrest leading to apoptotic cell death as demonstrated by the detection of poly(ADP-ribose) polymerase cleavage in LNCaP cells. Moreover, SQ40 also inhibited androgen receptor translocation to nucleus which is important for the transactivation of its target gene, prostate-specific antigen (PSA) and resulted in a significant reduction of PSA secretion after the treatment. In addition, intraperitoneal injection of 5 and 10 mg/kg of SQ40 also significantly suppressed the LNCaP tumor growth on mouse xenograft model. Results from the present study suggest that the standardized total quassinoids composition from E. longifolia promotes anti-prostate cancer activities in LNCaP human prostate cancer cells.     

Eurycomanone and eurycomanol,quassinoids from the roots of Eurycoma longifolia

From the roots of Eurycoma longifolia, used as an Indonesian folk medicine, two highly oxygenated quassinoids, named eurycomanone and eurycomanol were isolated. The structures of both new bitter principles were elucidated by NMR, MS, UV and IR.     

Plasmodium falciparum: In vitro interaction of quassin and neo-quassin with artesunate, a hemisuccinate derivative of artemisinin

Quassia amara L. (Family Simaroubaceae) is known to have several medicinal properties including the activity against malaria. An HPLC method was employed for purification of the biologically active quassinoids; quassin (Q) and neo-quassin (NQ), further characterized by MALDI-TOF analyses. Purified Q, NQ and the crude bark extract (S1) along with artesunate (AS) were studied for their in vitro anti-plasmodial activity. The in vivo toxicity studies at intraperitoneal doses with higher concentrations of the crude bark extract (S1) in Balb/C mice ruled out the apprehension of toxicity. Interaction studies between the test compounds among themselves (Q + NQ) and individually with artesunate (AS + Q, AS + NQ), were carried out in vitro at four ratios (1:5, 1:2, 2:1 and 5:1) on chloroquine sensitive (MRC-pf-20) and resistant (MRC-pf-303) strains of Plasmodium falciparum. The crude bark extracts of Q. amara exhibited higher P. falciparum inhibitory activity (IC₅₀ = 0.0025 μg/ml) as compared to that of the isolated compounds, quassin (IC₅₀ = 0.06 μg/ml, 0.15 μM), neo-quassin (IC₅₀ = 0.04 μg/ml, 0.1 μM) and also to the positive control, artesunate (IC₅₀ = 0.02 μg/ml, 0.05 μM). The in vitro drug interaction study revealed the compounds, quassin and neo-quassin to be additive to each other. At lower ratios, artesunate was found to be a potential combination partner with both the compounds. It was interesting to note that none of the combinations exhibited antagonistic interactions. This phenomenon offers the opportunity for further exploration of novel therapeutic concentrations and combinations.